A new standard in
breast cancer staging.
A new standard in breast cancer staging
The tiny particles of the Magtrace® node marker are optimised to take the same path a spreading cancer cell would through the lymphatic system, making it an ideal tracer for sentinel lymph node biopsy procedures.
Flexible. Accurate.
Magtrace® node marker for sentinel node mapping
The Magtrace® node marker is a liquid tracer that has been developed specifically for sentinel node biopsies. Detected by our Sentimag® localisation system, this non-radioactive tracer directs surgeons to the first draining lymph nodes most likely to contain cancer to help determine if it has spread.
This simple liquid allows any patient or any hospital, regardless of location, to access the highest standard in breast cancer staging.
Overview
Magtrace® node marker features + benefits
Better for patients
Just one injection required, compared to radioisotope and blue dye.
Highly versatile
Can be injected up to 7 days or as little as 20 minutes before surgery.
Perfectly optimised
Particles provide accurate target in the lymph nodes.
Save patient pain
Inject 20 minutes before surgery while patient is anaesthetised.
Safe and non-toxic
No unpleasant sensations or risk of anaphylaxis like blue dye.†
No radioactivity
None of the health or logistical implications associated with radioisotopes.
Clinical Testimonial
...a real game-changer in the way we treat breast cancer in the United States.
400+ hospitals
70,000+ patients
35+ countries
Join the hundreds of physicians using the Sentimag® platform and Magtrace® node marker to give their patients the best possible care.
References
*† Data and clinical references on file at Endomag.
Indications may vary in different countries; please either visit our indications page, consult the appropriate IFU or your local distributor for more information.